8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
Apr 24, 2026·SEC
Sana Biotechnology, Inc.(SANA)Earnings, Financials & Key Ratios
SANA•NASDAQ
$3.56
Price updated Jul 2, 2026
AboutSana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.Show more
- Revenue$0
- EBITDA-$178M+30.2%
- Net Income-$244M+8.5%
- EPS (Diluted)-0.96+17.2%
- ROE-118.7%-19.7%
SANA Price & Volume
Sana Biotechnology, Inc. (SANA) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Threatens Clinical Pipeline Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and clinical execution
Key Thesis Takeaways
- Sana Biotechnology remains in a high-risk, pre-revenue phase characterized by significant R&D expenditure and a rapidly depleting cash position.
- While the company continues to advance its hypoimmune platform, the lack of commercial revenue and a negative $1.9 billion retained earnings balance suggest an existential reliance on external financing.
- Investors should monitor the company's ability to reach critical clinical milestones before its $83.8 million cash reserve is exhausted.
Verdict Logic
the company's precarious financial position, highlighted by a dwindling cash balance of $83.8 million against persistent quarterly losses, suggests significant dilution or insolvency risks for long-term shareholders.
SANA Growth Metrics
Sana Biotechnology, Inc. (SANA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-15.96%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-4.55%
Return on Capital
10 Years-43.34%
5 Years-45.22%
3 Years-51.17%
Last Year-48.12%
SANA Recent Earnings
Sana Biotechnology, Inc. (SANA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.14+6.7%
$0.15
Rev
—
—
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.16-23.1%
$0.13
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.15+16.7%
$0.18
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.16+20.0%
$0.20
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.14vs $0.15+6.7% | — |
| Q2 2026 | Mar 3, 2026 | $0.16vs $0.13-23.1% | — |
| Q4 2025 | Nov 6, 2025 | $0.15vs $0.18+16.7% | — |
| Q3 2025 | Aug 11, 2025 | $0.16vs $0.20+20.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Sana Biotechnology, Inc. (SANA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.56 | $990.72M | -3.71 | — | — | -118.7% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $55.62 | $5.36B | -8.60 | -89.97% | -13856.54% | -30.88% | — | |
| $33.48 | $3.44B | -41.33 | 120.01% | -49.17% | -5.89% | — | |
| $3.28 | $321.13M | -1.82 | 25.39% | -281.59% | -677.39% | — | |
| $17.24 | $1.93B | -4.52 | 16.92% | -597.04% | -57.27% | — |
Compare SANA vs Peers
Sana Biotechnology, Inc. (SANA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SANA SEC Filings & Documents
Sana Biotechnology, Inc. (SANA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SANA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SANA Frequently Asked Questions
Sana Biotechnology, Inc. (SANA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is SANA profitable?
Sana Biotechnology, Inc. (SANA) reported a net loss of $242.0M for fiscal year 2025.
Dividend & Returns
What is SANA's return on equity?
Sana Biotechnology, Inc. (SANA) has a return on equity (ROE) of -118.7%. Negative ROE indicates the company is unprofitable.
What is Sana Biotechnology, Inc.'s free cash flow?
Sana Biotechnology, Inc. (SANA) had negative free cash flow of $133.6M in fiscal year 2025, likely due to heavy capital investments.